Association of Immune Checkpoint Inhibitors with Respiratory Infections: A Review

Recently, immune checkpoint inhibitors (ICIs) have been used to treat many types of cancer, including lung cancer. In addition to advanced-stage non-small cell lung cancer without driver gene mutations, combined chemotherapy and immunotherapy has been recommended in the initial treatment of advanced-stage small cell lung cancer. During treatment with ICIs, managing immune-related adverse events (irAE) can be problematic. Among these, ICI-related pneumonitis (ICI-P) is sometimes fatal, and caution is required [1].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Complications of Treatment Source Type: research